We report five individuals with loss-of-function of the X-linked AMMECR1: a girl with a balanced X-autosome translocation and inactivation of the normal X-chromosome; two boys with maternally inherited and de novo nonsense variants; and two half-brothers with maternally inherited microdeletion variants. They present with short stature, cardiac and skeletal abnormalities, and hearing loss. Variants of unknown significance in AMMECR1 in four male patients from two families with partially overlapping phenotypes were previously reported. AMMECR1 is coexpressed with genes implicated in cell cycle regulation, five of which were previously associated with growth and bone alterations. Our knockdown of the zebrafish orthologous gene resulted in
INTRODUCTION
AMMECR1 maps within the AMME (Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis) complex interval. AMME (MIM# 300194 ) is an Xq22.3 contiguous gene deletion syndrome encompassing about 20 genes (Supp. Figure S1 ) characterized by nephropathy (Alport syndrome, MIM# 301050), intellectual disability, midface hypoplasia, and elliptocytosis. Some affected individuals also present with hearing loss, ocular abnormalities, limb malformations, cardiac arrhythmia, and heart defects (Jonsson et al., 1998) .
The COL4A5 gene has been implicated in Alport syndrome, hearing loss, and eye abnormalities (Vaser, Adusumalli, Leng, Sikic, & Ng, 2016; Vitelli et al., 1999) , whereas variants in ACSL4 were associated with X-linked intellectual disability 63 (MRX63; MIM# 300387) (Gazou et al., 2013; Meloni et al., 2002) . The other clinical features of AMME, such as midface hypoplasia, elliptocytosis, limb malformations, cardiac arrhythmia, and heart defects, could be associated with the remaining neighboring genes, including AMMECR1 (Supp. Figure S1 , Table 1 , and Supp. Table S3 ).
A family with two affected male individuals, the patient and one of his maternal uncles, who had partially overlapping phenotypes, that is, midface hypoplasia, proportionate short stature, hearing loss, and elliptocytosis with or without anemia, was recently described (BaselVanagaite et al., 2017) . The causative nature of the identified stop gain variant in AMMECR1 that induces skipping of 111 bp-long exon 2 is not clear. The investigated patient's X-CHROMOSOME carries 12 more rare exonic variants in particular a frameshift and a stop gain variant in MAGEB3 (pLI = 0.66, 0 loss-of-function (lof) variants identified compared with the 3.3 expected according to Exome Aggregation Consortium [ExAC] ) and the lof intolerant SLC16A2 (pLI = 0.93, 0 identified/8.4 expected) genes, respectively. Two half-brothers presenting elliptocytosis, midface hypoplasia, early speech, and language delay carrying a p.(Gly177Asp) missense variant in AMMECR1 that causes mislocalization of the encoded protein were also reported (Andreoletti et al., 2016) . These four cases were regrouped by OMIM under the identifier MFHEIN (midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis, MIM# 300990).
Here, we describe four new males and a female with variants that are predicted to lead to lof of the X-linked AMMECR1 gene and present with short stature, cardiac and skeletal abnormalities, and hearing loss. The female carries a balanced X-autosome translocation disrupting AMMECR1 and silencing of the normal X, whereas the males are hemizygous for a nonsense variant or a deletion encompassing AMMECR1. Our results support the involvement of AMMECR1 in a new syndrome and expand its associated phenotypes that group growth abnormalities with alterations of bones and heart.
MATERIALS AND METHODS

Enrollment
All samples used in this study were collected with written appropriate informed consent and approval of the local ethics committee.
Classical and molecular cytogenetic evaluation
G-banding of 550 resolution was performed on lymphocyte cultures using standard methods. Genomic array was performed using the Affymetrix Genome-Wide Human SNP-Array 6.0 or Human Genome comparative genome hybridization (CGH) array 4 × 44k (Agilent Technologies, Santa Clara, MA, USA). For patient 1, breakpoint localization was performed by fluorescence in situ hybridization (FISH) and array painting as described (Liehr, Heller, Starke, & Claussen, 2002; Moyses-Oliveira et al., 2015) and validated by FISH using bacterial artificial chromosome probe CTD-3066N24 (Thermo Fisher Scientific, Waltham, MA, USA) and whole-genome sequencing. X-chromosome inactivation was assessed as described (Sisdelli et al., 2016) .
Exome and whole genome sequencing and analysis
Patient 2 DNA was whole exome sequenced using the VCRome capture reagent as described (Yang et al., 2014) . Variants with MAF < 0.05% in controls cohorts (dbSNP, 1000 genome project, NHLBI GO Exome, ExAC) and predicted to be deleterious by at least one of the predictor SIFT (Vaser et al., 2016) , PolyPhen-2 (Adzhubei et al., 2013) , and/or UMD-Predictor (Salgado et al., 2016) were prioritized.
Segregation of variants was confirmed by Sanger sequencing. Patient 3 and his parents DNA samples were prepared using the Illumina TruSeq PCR-free library prep and sequenced on a HiSeqX sequencer (Illumina, San Diego, CA, USA) with paired end 150 bp reads. Reads were aligned to human reference genome assembly GRCh37 using ISACC aligner and variants were filtered using inheritance patterns, allele frequency, and molecular consequences. Variants were manually curated, and classified according to the American College of Medical Genetics and Genomics guidelines (Richards et al., 2015) . The identified pathological variants were submitted to ClinVar.
Cell lines, RNA, and quantitative RT-PCR
We established lymphoblastoid cell lines (LCLs) from the Brazilian patient (patient 1), her mother, and 10 unrelated Brazilian female controls; seven of which are carriers of balanced X-autosome translocations with different breakpoints (karyotypes described in Supp. 
Western blot
Fractionated protein extraction was performed as described (Settembre et al., 2011) . Protein (30 g) was resolved on 10% SDS-PAGE 
Morpholinos and zebrafish embryo manipulations
Zebrafish animal experimentation was approved by the Canton of Geneva Animal Experimentation Veterinary authority. Wild-type TU zebrafish were maintained in standard conditions (27 • C, 500 mS, pH 7.5). Embryos obtained by natural intercrossing were staged according to morphology (Kimmel, Ballard, Kimmel, Ullmann, & Schilling, 1995) .
To model a lof of AMMECR1, we designed three splice-blocking MO targeting the zebrafish ammecr1 pre-mRNA: (1) MO-E1I1- 
Functional network analysis
We utilized Genomescale Integrated Analysis of gene Networks in Tissues (GIANT) to assess tissue-specific functional interactions (Greene et al., 2015) . Enrichment of biological processes and cellular components was determined using Enrichr (Chen et al., 2013) . The same analysis was repeated for GAPDH and RGAG1 genes. 
Expression of GFP-AMMECR1 in HeLa cells
pcDNA
Gene expression in early mouse embryos
Balb/c mice experimentation was approved by the local committee for animal care. Immediately after the postnatal females euthanasia, 9.5 GD embryos were collected and fine dissected using a needle under a stereoscope. Material from 35 embryos were pooled in five samples per tissue (prosencephalon, heart, and somite). RNA was isolated using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA). 
RESULTS
Clinical descriptions
The phenotypes of the five affected individuals identified in this report are compared with the previously published MFHEIN cases and AMME deletion syndrome patients in Table 1 and Supp. Figure   S2 , Table 1 , and Supp. Table S3 ). At the same age, whole-skeleton Xray revealed wormian bones in the skull, bone age delay, thoracolumbar scoliosis, diffuse bone demineralization with peripheral osteopenia showing looser zones in the first metatarsals and metacarpals bilaterally and also in iliac bones. The distal phalanges were cone shaped with irregularities, and bones of hands, feet, and long bones presented hyperdense epiphyses and metaphyses (Supp. Figure S2 , Table 1 , and Supp. Table S3 ). At 7 years of age, a brain MRI showed no abnormalities, and neuropsychological evaluation using the WISC IV revealed normal intelligence (IQ 91). At the same age, GH replacement therapy was initiated, and the patient responded to the treatment. The echocardiogram showed an ostium primum atrial septal defect with thin aneurysmal septal tissue. Different medical examinations at ages 3 and 9 revealed tachycardia at rest. The immunological evaluation at 8 years of age showed normal immunoglobulin levels with positive response to pneumococcal vaccine and normal lymphocyte numbers (CD3, CD4, and CD19). The central memory and peripheral CD8+T cells were reduced (1% and 10%, respectively). Facial features coarsened with age. At 10 years of age, bilateral neurosensorial hearing loss for high frequencies was detected, and CT scan showed normal temporal bones.
Patient 2 was born in America. He presented with motor delay, speech delay, hypotonia, short stature and failure to thrive, dysmorphia, congenital heart disease with atrial septal defect, ureterocele and hypercalcemia, radioulnar synostosis, small penis, and failed hearing screen for high pitch (Figure 1 , Table 1 , and Supp. Table S3 ). Patient 3 is of mixed African-American, Cuban, Polish, and German ancestry.
He presented with hypotonia, short stature and failure to thrive, dysmorphia included crowded midface, pectus excavatum, flared rib cage, chordee and hypospadia, and mild sensorineural hearing loss (Figure 1 , Table 1 , and Supp. Table S3 ). The two remaining affected individuals Table 1 , and Supp. Table S3 ).
Molecular findings
Chromosome and SNP-array analysis of patient 1 revealed a de novo balanced translocation involving chromosomes X and 9 (46,X,t(X;9)(q23;q11.2); Supp. Figure S3A ). Array-CGH of the microdissected and amplified DNA from the derivative chromosomes mapped the Xq23 breakpoint to a 62 kb region (chrX:110,259,238-110,321,368; hg38; Supp. Figure S3B ). The Xq23 and the 9q12 breakpoints were validated by FISH (Supp. Figure S3D ). We then sequenced the patient's whole genome to finely map the breakpoints.
Eleven chimeric inserts with paired-end reads mapping to different chromosomes and two soft clipped sequences, that is, reads with portions of the read not part of the alignment (Supp. and der(9) chromosome, respectively, with a loss of seven nucleotides (Figure 2A and Supp. Figure S4 ). The 9q12 breakpoint affected a region of repeated nature that could not be unequivocally mapped;
however, the corresponding soft-clipped reads are consistent with chromosome 9 nucleotide sequences. HUMARA and 5-ethynyl-2 ′ -deoxyuridine (EdU) incorporation showed an extremely skewed inactivation (100:0) with the normal X-chromosome inactivated in all metaphases analyzed (Supp. Figure S5 ). As the AMMECR1 and RGAG1 genes do not generally escape X-chromosome inactivation (Carrel & Willard, 2005; Cotton et al., 2015) , only the translocated allele would be transcriptionally active. We assessed expression of AMMECR1 and RGAG1 by RT-qPCR in LCLs from the patient, her mother, and Brazilian female controls. Although AMMECR1 was expressed in LCLs from the mother and 10 controls (CT mean 30.1; CT SD 0.8, ΔCT AMMECR1-GAPDH mean 13.3; ΔCT AMMECR1-GAPDH SD 0.9), we failed to detect AMMECR1 gene expression in the patient's cells ( Figure 2B ). On the contrary, we found no differences in expression levels of RGAG1 in the assessed LCLs ( Figure 2B (Table 1 and Supp. Table S3 ).
AMMECR1 interaction network
The AMMECR1 protein is conserved in vertebrates, whereas proteins containing the C-terminal part of human AMMECR1, named AMMECR1 domain, are present in eukaryotes, bacteria and archea (Supp. Figure S6A ). The human AMMECR1 encodes a 33 kDa protein of unknown function that harbors two RAGNYA folds known to interact with nucleic acid (Balaji & Aravind, 2007) . The phylogeny of proteins containing RAGNYA traces this domain back to the last universal common ancestor of all extant life forms (Balaji & Aravind, 2007 ). An AMMECR1 paralog, AMMECR1L, appeared in tetrapods.
Like its homolog, the 68% similar to AMMECR1 (Supp. Figure S6B) autosomal AMMECR1L is «extremely intolerant» to lof variation according to ExAC with a pLI = 1.0. AMMECR1L is overexpressed in LCLs from patient 1 ( Figure 2B , P < 0.05). Of note, her mother presented a similarly elevated expression level when compared with the female Brazilian controls ( Figure 2B ). This also impacted the level of the encoded protein as Western blotting showed that AMMECR1L was higher in cells of patient 1 than in cells from a control individual ( Figure 2C and Supp. Figure S7 ). Our results suggest that AMMECR1L could potentially partially compensate for loss of AMMECR1. Alternatively, the elevated AMMECR1L expression level of patient 1 could be caused by a coincidental expression quantitative trait loci passed down from her mother.
In line with nucleic acid binding, transfection assay in HeLa and HEK293 cells showed a nuclear sublocalization of GFP-tagged AMMECR1 (Supp. Figure S8 ). The Western blotting results were less straightforward as they showed that the tagged AMMECR1 was present in both the cytoplasmic and nuclear fractions (Supp. Figures   S7 and S9 ). These results possibly reflect exogenous higher expression levels as the endogenous AMMECR1L paralog was exclusively identified in the nuclear extract of LCL cells of both patient 1 and a control individual (Supp. Figure S7) . As the major antibody-reactive band ran slightly above 60 kDa and as AMMECR1L is predicted to be 31 kDa in size, we hypothesized that AMMECR1 proteins are creating dimers insensitive to SDS-PAGE (Supp. Figure S7 ). Consistent with our hypothesis a ≈ 30 kDa reactive band could be identified upon longer exposure. This was confirmed when assessing transfected GFP-AMMECR1; although in most experiments the major reactive band ran at approximately 60 kDa, in some experiments the reactive band corresponded to twice the singleton mass of this tagged proteins, that is, 120 kDa (Supp. Figure S7 ). Our results suggest that a fraction of AMMECR1 and AMMECR1L proteins are present in the nuclear fraction of the cells as dimers.
We used the GIANT database (Greene et al., 2015) to predict the AMMECR1 functional network. Seventy-seven genes are interacting with AMMECR1 directly or with a maximum of one intermediate node (Supp. Figure S10 and Supp. Table S5 ). This list of genes was enriched for Gene Ontology (GO) Biological Process term "mitotic cell cycle"
(GO:0000278; Fisher exact test P = 2.1 × 10 −21 ; z-score = −2.3;
combined score = 93.78) and GO Cellular Component term "nucleoplasm" (GO:0005654; P = 6.2 × 10 −14 ; z-score = −2.26; combined score = 57.71; Supp. Table S6 -S7). The list of genes that interact with AMMECR1L, the AMMECR1 paralog in humans, presents "regulation of transcription involved in G1/S transition of mitotic cell cycle"
(GO:0000083) as the most enriched GO term (Supp. Table S8-S10).
Other network models generated as controls with the same settings do not present enrichment of cell cycle related biological processes and cellular compartments, suggesting that the association between AMMECR1 and these GO terms is specific (Supp. Table S11-S16). These results further support a causative role of lof of AMMECR1 in growth and bone phenotypes.
AMMECR1 knockdown in zebrafish
The zebrafish embryo is an emerging in vivo model for translational medicine (Chetaille et al., 2014; Golzio et al., 2012; Payne et al., 2014; Stewart et al., 2014) . To further assess the consequences of absence of AMMECR1 expression, we used a morpholino ( paralog in non-tetrapod vertebrates. Consistent with this hypothesis, AMMECR1L is expressed at higher levels than AMMECR1 despite largely overlapping expression pattern according to GTEx. We similarly found that Ammecr1l was more expressed than Ammecr1 in mice embryonic tissues affected in the patients (Supp. Figure S15 ).
DISCUSSION
We found through breakpoint mapping of an X-autosome balanced translocation, exome and genome sequencing and array-CGH that lof of AMMECR1 is associated with a novel syndrome that groups heart, bone and growth alterations and in one family elliptocytosis. Although failure to thrive and skeletal alterations are common to our patients and the four previously reported MHFEIN individuals (Basel-Vanagaite et al., 2017; Andreoletti et al., 2016) , psychomotor delay, elliptocytosis, cardiac, and renal alterations for example are present only in a subset of affected individuals (Table 1 and Supp. Table S3 Although little is known about the function of AMMECR1 and AMMECR1L, available information suggests roles in control of cell division. AMMECR1 expression is upregulated in response to estrogen and activin A, a member of the TGF family, in breast cancer cells and embryonic stem cells, respectively (Tan et al., 2014; Tsai et al., 2011) . It is targeted by ELAV1, a protein that regulates the stability and translation of a variety of mRNAs encoding stress-response and proliferative proteins (Abdelmohsen et al., 2009) . The silencing of the AMMECR1-like paralog in HeLa cells induces a G1 arrest phenotype (Kittler et al., 2007) , whereas expression of both the Saccharomyces cerevisiae (YOR289W) and Schizosaccharomyces pombe (SPAC688.03c.1) orthologs peaks in G1 (Marguerat et al., 2012; Santos, Wernersson, & Jensen, 2015) . YOR289W is sensitive to drugs that block translation, is interacting genetically with translation regulators, and is synthetic lethal with GCL7, a spindle checkpoint regulator gene (Cherry et al., 2012) . Correspondingly, the AMMECR1 functional network established using GIANT is enriched for genes associated with the mitotic cell cycle, the G1/S transition in particular, and DNA replication and packaging and contains five genes (ZWINT, CDC6, PSAT1, EZH2, and SMC2) associated with perturbations of intrauterine growth and bone maturation. Our findings suggest that AMMECR1 is potentially involved in cell cycle control and linked to a new syndrome with growth, bone and heart alterations.
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